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Abstract
To establish the maximum tolerated dose (MTD), dose- limiting toxicities (DLT), 
safety profile, and anti- tumor efficacy of RAF265. We conducted a multicenter, 
open- label, phase- I, dose- escalation trial of RAF265, an orally available RAF 
kinase/VEGFR- 2 inhibitor, in patients with advanced or metastatic melanoma. 
Pharmacokinetic (PK) analysis, pharmacodynamics (PD) and tumor response as-
sessment were conducted. We evaluated metabolic tumor response by 18[F]- 
fluorodeoxyglucose- positron- emission tomography (FDG- PET), tissue biomarkers 
using immunohistochemistry (IHC), and modulators of angiogenesis. RAF265 has 
a serum half- life of approximately 200 h. The MTD was 48 mg once daily given 
continuously. Among 77 patients, most common treatment- related adverse effects 
were fatigue (52%), diarrhea (34%), weight loss (31%) and vitreous floaters (27%). 
Eight of 66 evaluable patients (12.1%) had an objective response, including seven 
partial and one complete response. Responses occurred in BRAF- mutant and 
BRAF wild- type (WT) patients. Twelve of 58 (20.7%) evaluable patients had a 
partial metabolic response. On- treatment versus pretreatment IHC staining in 23 
patients showed dose- dependent p- ERK inhibition. We observed a significant 
temporal increase in placental growth factor levels and decrease in soluble vascular 
endothelial growth factor receptor 2 (sVEGFR- 2) levels in all dose levels. RAF265 
is an oral RAF/VEGFR- 2 inhibitor that produced antitumor responses, metabolic 
responses, and modulated angiogenic growth factor levels. Antitumor activity oc-
curred in patients with BRAF- mutant and BRAF- WT disease. Despite low activity 
at tolerable doses, this study provides a framework for the development of pan- 
RAF inhibitors and modulators of angiogenesis for the treatment of melanoma.
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Introduction
Melanoma remains the most common cause for skin- 
cancer related mortality with over 10,000 deaths anticipated 
in 2016 [1]. The incidence of melanoma has been steadily 
rising over the last several decades [1]. At the time this 
trial was launched in 2006, patients with metastatic mela-
noma had a poor 5- year survival rate of less than 10% 
with a median survival of only 6–9 months [2]. The poor 
survival of patients with advanced or metastatic melanoma 
was primarily due to insensitivity to cytotoxic chemo-
therapy agents, such as dacarbazine (DTIC). High- dose 
interleukin 2 (HD- IL2) produces durable responses in 
5–8% of patients with an overall response rate of 16–22% 
[3, 4], but the majority of patients were either not suit-
able for or did not have access to this therapy.
The discovery of somatic activating mutations in the BRAF 
gene in several cancers [5], including approximately 50% 
of melanomas [6, 7], provided the genetic foundation for 
the development of targeted treatment approaches for patients 
with BRAF- mutant cancers. Activating mutations at V600 
codon of the BRAF gene, most commonly BRAFV600E, result 
in dramatically enhanced activity of the BRAF kinase and 
constitutive activation of the MAP kinase (MAPK) pathway 
enabling tumor growth. Targeting the MAP kinase pathway 
in patients with advanced melanoma was first attempted 
with sorafenib, either alone or in combination with chemo-
therapy with ultimately disappointing results [8–10], making 
it clear that more selective inhibitors of BRAF were needed.
RAF265 is a novel, orally active, small molecule kinase 
inhibitor with potent activity against mutant and wild- 
type BRAF, CRAF and additional anti- angiogenic activity 
through inhibition of vascular endothelial growth factor 
type 2 (VEGFR- 2) in preclinical models [11–13]. Pan- RAF 
inhibitors show activity in preclinical models including 
those using BRAF- mutant and BRAF- WT melanomas [14]. 
Inhibition of VEGFR- 2 using axitinib also showed activity 
in a phase II trial in patients with metastatic melanoma 
[15] and the anti- VEGF antibody bevacizumab enhanced 
the activity of cytotoxic chemotherapy in a randomized 
phase II trial [16], particularly in patients with M1c disease 
especially with elevated LDH. Based on the critical need 
for effective new treatment approaches for patients with 
BRAF- mutant and BRAF- WT locally advanced or metastatic 
melanoma, we conducted this first- in- human phase I study 
of RAF265 in this treatment population.
Patients and Methods
Patients
Patients with histologically confirmed melanoma; measur-
able locally advanced or metastatic disease; age ≥ 18 years; 
an Eastern Cooperative Oncology Group performance 
status of 0 or 1; available tumor to determine BRAF 
mutation status; no prior treatment with MEK, VEGF/
VEGFR, or RAF inhibitors; no history or presence of 
brain metastases; a minimum of 4 weeks elapsed since 
any major surgery or prior anticancer/investigational 
therapy; and adequate bone marrow, liver and renal func-
tion were eligible. Patients signed an institutional review 
board–approved informed consent form.
Study design
This study was an open- label, multicenter, nonrandomized, 
phase I/II, dose- escalation study of orally administered 
RAF265. The study was designed primarily to determine 
the maximum tolerated dose (MTD) and/or or recom-
mended phase II dose (RP2D), dose- limiting toxicities 
(DLTs), and safety of oral dosing of RAF265 in patients 
with locally advanced or metastatic melanoma using dif-
ferent dosing schedules. The study was comprised of two 
phases: A dose escalation phase and an expansion phase 
at the MTD/RP2D. The dose- escalation phase was guided 
by pharmacokinetics (PK), pharmacodynamics (PD) and 
safety. In the dose escalation phase, cohorts 1- 7.1 were 
administered RAF265 as a single oral dose on Day 1 of 
the PK run- in period followed by one loading dose of 
RAF265 on Cycle 1 Day 1, and by lower once daily doses 
of RAF265 starting on Cycle 1 Day 2. In the expansion 
phase (cohort 7.1) the PK run in was omitted and patients 
received a loading dose in 3 divided doses followed by 
lower daily dose beginning on Cycle 1, Day 2. The cycle 
length was 28 days in all cohorts. Here, we report the 
dose escalation and expansion arm investigating a con-
tinuous treatment regimen.
Study approach
Medical history and demographics were collected at screen-
ing. The safety of study medication was evaluated on the 
basis of rate, type, severity graded in accordance with 
NCI CTCAE version 3.0. Safety assessments consisted of 
collecting all AEs, serious adverse events (SAEs) with their 
severity and relationship with study drug, and pregnan-
cies. They included the regular monitoring of hematology, 
blood chemistry and urine performed at the study center/
central laboratory and regular assessments of vital signs, 
physical condition, body weight, performance status, and 
cardiac data (i.e. electrocardiogram (ECG)/echocardiogram 
(ECHO)). Abnormalities in clinical laboratory tests that 
were considered clinically significant by the Investigator 
were recorded on the AE CRF. Dose- limiting toxicities 
(DLTs) were defined for various organ systems and other 
clinically relevant adverse effects (Table S1). The DLT 
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window was the first cycle while AEs were captured for 
the entire course of treatment. Evaluation of tumor response 
was conducted at Baseline, and at the end of every 8 weeks 
of treatment. Response was assessed using the Response 
Evaluation Criteria in Solid Tumors (RECIST) 1.0. A 
complete or partial response (CR or PR) was confirmed 
at least 28 days after the first assessment that documented 
response and every two cycles thereafter until disease 
progression, initiation of confounding anticancer therapy, 
death, loss to follow- up, withdrawal of consent, or study 
termination. All patients discontinuing from the study 
for progressive disease were to have their disease progres-
sion documented by radiologic evaluation.
Pharmacokinetics
Blood samples for plasma RAF265 concentration deter-
mination were collected on cycle 1, day 1 and day 15, 
and on cycle 2, day 1. All PK analyses were based on 
concentrations of unchanged RAF265 in plasma. PK param-
eters included the maximum observed concentration (Cmax), 
time to reach Cmax (Tmax), area under the curve from 
time 0 to last measurable concentration (AUClast), time 
point of the last measurable concentration (Tlast), and 
terminal half- life of elimination phase (T1/2). Cycle 1 Day 
1 and day 15, reported PK parameters include Cmax, Tmax, 
AUClast and Tlast. Following log- transformation, the PK 
parameters AUC and Cmax from the PK run- in were ana-
lyzed separately using a mixed effects model fitting terms 
for dose and patient (Patient treated as a random factor)- 
ln(PK parameter) = a + b*ln(Dose)+error. In this model, 
the dose- exposure relationship is mainly characterized by 
the slope parameter b. A slope lower (higher) than 1 
indicates an under (over) proportional dose- exposure 
relationship. The point estimate and associated 90% CI 
for the slope parameter were determined for safety 
considerations.
Pharmacodynamics and biomarker 
assessment
Pharmacodynamic markers were examined using peripheral 
blood samples, tumor and nevi biopsies (when available) 
and tumor imaging. BRAF mutation status was determined 
by Sanger sequencing. Pharmacodynamic markers analyzed, 
in available tumor/nevus samples obtained before treat-
ment or archival tissue and during treatment on cycle 1, 
day 8 or day 15, including cytoplasmic p- MEK, p- ERK, 
BIM, c- KIT, p- AKT473, pS6 and PTEN, and nuclear 
p- ERK, Ki- 67, PARP, cyclin D1, MITF, p27, and p53. 
Biomarker expression was determined by calculating the 
percentage of change in the H- score (14) between on- 
treatment and fresh/archival pretreatment specimens. Blood 
levels of VEGFR- 2 and were assessed before and at multiple 
time points while on treatment using enzyme- linked 
immunosorbent assay (ELISA). Tumor imaging using 
18[F]- FDG- PET to determine effects of RAF265 on tumor 
metabolic activity was performed within 2 weeks prior 
to treatment start (baseline), and on- treatment on C1D15 
and C1D28. Changes in standard uptake value (SUV) 
were determined by a blinded, independent central imag-
ing review panel. Complete metabolic response (CMR) 
was complete resolution of tumor FDG- PET uptake so 
SUV is the same as background. Partial metabolic response 
(PMR) decrease in sum of the tumor SUV of ≥25% from 
the baseline scan. Progressive metabolic disease (PMD) 
was defined as an increase in tumor SUV of ≥25% from 
the baseline scan, or the appearance of new FDG- PET 
uptake in metastatic lesions. Stable metabolic disease (SMD) 
was defined as a change in tumor SUV between the PMR 
and PMD criteria.
Statistical analyses
A Bayesian Logistic Model with five- parameter overdose 
control methodology [17] was used to calculate loading 
dose, maintenance dose and dose escalation until the MTD 
was reached with the goal to enroll at last 6 patients at 
the MTD. The MTD was defined as the dose level with 
16–33.3% probability of a DLT. Using the statistical 
approach the study had a 13.8% chance of identifying 
the true MTD at DL6. Descriptive statistic were used for 
the analysis of PK, biomarker analysis and tumor response 
data.
Results
Patient characteristics and study drug 
exposure
A total of 77 patients were enrolled in this study at four 
sites in the US and one site in Europe, and received one 
or more doses of RAF265. Patient demographics and 
baseline characteristics are listed in Table 1. Among 77 
patients, 39 (51%) had BRAF- mutant and 33 (43%) had 
BRAF wild- type melanoma. The BRAF mutation status 
was unknown for five patients. Sixty five (85.5%) patients 
had at least one prior line of treatment, and 43 (57%) 
had at least 2 prior lines of treatment before enrolling 
in this trial. Patients were enrolled in 8 cohorts corre-
sponding to different dose levels (1 through 7 [Table S2] 
with a 7–10 days run- in period, followed by a loading 
dose (LD) and a daily maintenance dose (MD). Cohort 
7.1 omitted the run- in period and administered the LD 
in 3 divided doses over 24 h and then received the same 
daily maintenance dose as in Cohort 7. Twenty- six patients 
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(40%) received 4 or more cycles and 13 patients (16.9%) 
received 7 or more cycles of RAF265 with a mean expo-
sure time of 6.1 (±12) months.
Safety
Treatment–related AEs that occurred in ≥10% of patients 
are listed in Table 2. The most commonly reported AEs 
(≥30% of patients) were fatigue (51.9%), diarrhea (35.1%) 
and weight loss (31.2%). Seven dose- limiting toxicities 
occurred in 6 patients, including a grade 3 lipase eleva-
tion and grade 2 toxic retinopathy at dose level 6 (48 mg 
MD) and a grade 3 ataxia and vitreous floaters in one 
patient, grade 3 diarrhea, and two grade 4 pulmonary 
emboli at dose levels 7 and 8 (67 mg MD). A total of 
30/77 (39%) reported AEs requiring dose adjustment or 
interruption, most commonly fatigue in 6 patients (7.8%), 
diarrhea in 5 (6.5%) patients, photopsia, vitreous floaters, 
hypertension, decreased appetite and nausea in 4 (5.2%) 
patients each, and thrombocytopenia in 3 patients (3.9%). 
Based on initial results of 9 patients in dose level 7, a 
dose expansion cohort was added at 67 mg QD (without 
initial run- in period). The overall rate of grade 3 and 4 
toxicities was 53.2%. The overall rate of RAF265 related 
grade 3 and 4 toxicities in dose level 7 and 7.1, including 
7 of 19 (36.8%) patients with thrombocytopenia and 4 
(21%) patients with diarrhea was unacceptable (Table 3). 
Specific serious adverse events (SAEs) occurred in 29/77 
(37.7%) patients, most commonly (in ≥2 patients) pul-
monary embolism in 5 (6.5%) followed by dehydration 
in 4 (5.2%), thrombocytopenia in 3 (3.9%), and constipa-
tion, and retinopathy in 2 (2.6%) patients each. We 
observed delayed and prolonged, post cycle 1 toxicities 
in dose level 7 and 7.1. The prior probability of DLTs 
in these cohorts was below the threshold maximum at 
the time the final number of patients was enrolled. As 
described previously [17], post cycle 1 toxicities were 
therefore used to inform the Bayesian model used in this 
study, and the maximum- tolerated dose (MTD) was 
declared at 48 mg QD (dose level 6). There were 5 (6.5%) 
deaths reported within 28 days of last administration of 
the study drug, none of which were deemed to be treat-
ment related.
Pharmacokinetics
RAF265 had an extensive distribution phase and a long 
half- life of approximately 200 h or 8 days (Table S3). 
Preclinical studies indicated efficacious concentration (Ceff) 
was 4127 ng/mL, which corresponded to estimated plasma 
Ceff between MTD of 48 mg (dose level 6) and 67 mg 
(dose level 7/7.1). In general, the mean observed maximum 
plasma concentration (Cmax) and area under the curve 
(AUC) increased nearly proportionally with dose.
Antitumor efficacy
A total of 66 patients across all dose levels were evaluable 
for antitumor response to RAF265. Among these, there 
were a total of eight RECIST defined responses resulting 
in an objective response rate (ORR) of 12.1% across all 
dose levels (Table 4). These included seven partial responses 
(PR) and one complete response (CR). Four PR were 
observed in 39 patients with BRAFV600E mutation and 
two PR and one CR in 33 patients with BRAF- WT mela-
nomas and one PR in a patient with an unknown BRAF 
mutation status (Table 4). The median duration of response 
was 18.3 months (range, 1.4–51.7 months) in 
responders.
Pharmacodynamic and biomarker analyses
The effect of RAF265 on tumor metabolic activity was 
assessed by tumor imaging using 18[F]- FDG- PET. Baseline 
and evaluable C1D15 and C1D28 FDG- PET scans were 
available in 71, 65 and 58 patients, respectively. Across 
all dose levels, 12 of 58 (20.7%) patients exhibited a partial 
metabolic response (PMR) (Fig. 1), 36 (62.1%) had stable 
metabolic disease (SMD) and 10 (17.2%) had progressive 
Table 1. Demographics, clinical data and BRAF mutation status of pa-
tients included in this study.
Demographic/variable N, (%)
Total population 77 (100%)
Age (years)
Median 60
Min- max 26–83
Sex
Male 43 (55.8)
Female 34 (44.2)
BRAF mutation status
Mutated 39 (50.6)
Wild- type 33 (42.9)
Unknown 5 (6.5)
ECOG performance status n (%)
Grade 0–1 breakdown into 0 and 1? 77 (100)
Prior lines of treatment (n)
0 11 (14.5)
1 22 (28.9)
2 16 (21.1)
3 27 (35.5)
N/A 1 (1.3)
Stage
III or IIIC 6 (7.8)
IV 40 (51.9)
IV a 3 (3.9)
IV b 9 (11.7)
IV c 19 (24.7)
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Table 2. Frequency of treatment- related adverse events across dose levels.
Preferred term
DLs 1- 4 
N = 20 
n (%)
DL 5 
N = 15 
n (%)
DL 6 
N = 23 
n (%)
DLs 
7 and 7.1 
N = 19 
n (%)
All 
patients 
N = 77 
n (%)
Fatigue 7 (35.0) 7 (46.7) 13 (56.5) 13 (68.4) 40 (51.9)
Diarrhea 2 (10.0) 3 (20.0) 7 (30.4) 15 (78.9) 27 (35.1)
Weight decreased 2 (10.0) 1 (6.7) 10 (43.5) 11 (57.9) 24 (31.2)
Vitreous floaters 1 (5.0) 3 (20.0) 9 (39.1) 8 (42.1) 21 (27.3)
Dysgeusia 1 (5.0) 1 (6.7) 9 (39.1) 8 (42.1) 19 (24.7)
Nausea 2 (10.0) 1 (6.7) 8 (34.8) 8 (42.1) 19 (24.7.)
Photopsia 1 (5.0) 4 (26.7) 6 (26.1) 8 (42.1) 19 (24.7)
Decreased appetite 0 (0.0) 0 (0.0) 8 (34.8) 9 (47.4) 17 (22.1)
Thrombocytopenia 1 (5.0) 0 4 (17.4) 11 (57.9) 16 (20.8)
Muscle spasms 2 (10.0) 3 (20.0) 5 (21.7) 5 (26.3) 15 (19.5)
Vomiting 2 (10.0) 0 6 (26.1.4) 7 (36.8) 15 (19.5)
Hypertension 3 (15.0) 0 5 (21.7) 4 (21.1) 12 (15.6)
Abdominal pain 1 (5.0) 0 3 (13.0) 3 (15.8) 7 (9.1)
Constipation 1 (5.0) 1 (6.7) 2 (8.7) 3 (15.8) 7 (9.1)
Lipase increased 1 (5.0) 2 (13.3) 4 (17.4) 2 (10.5) 7 (9.1)
Dizziness 1 (5.0) 1 (6.7) 4 (17.4) 3 (15.8) 9 (11.7)
Rash 0 1 (6.7) 4 (17.4) 1 (5.3) 6 (7.8)
Neutropenia 0 0 0 5 (26.3) 5 (6.5)
Alopecia 2 (10.0) 1 (6.7) 1 (4.3) 0 4 (5.2)
Dehydration 0 0 3 (13.0) 1 (5.3) 4 (5.2)
Dry mouth 0 0 1 (4.3) 3 (15.8) 4 (5.2)
Dyspnea 0 0 2 (8.7) 2 (10.5) 4 (5.2)
Hemoglobin decreased 0 0 2 (8.7) 2 (10.5) 4 (5.2)
Table 3. Frequency of treatment- emergent grade 3/4 events across dose levels.
Grade 3/4 toxicities
DLs 1–5 
(≤24 mg; N = 35) 
n (%)
DL 6 
(48 mg; N = 23) 
n (%)
DLs 7 and 7.1 
(67 mg; N = 19) 
n (%)
All DLs 
N = 77 
n (%)
Total (n) 3 15 26 41 (53.2%)
Hematological – 1 (4.3%) 11 (57.9) 12 (29.2%)
Thrombocytopenia – 0 7 (36.8) 7 (17.1%)
Neutropenia – 1 (4.3%) 3 (15.8) 4 (9.8%)
Pancytopenia 1 (5.3) 1 (2.4%)
Fatigue – 3 (13) 3 (15.8) 6 (14.4%)
Diarrhea – – 4 (21.1) 4 (9.8%)
Hypertension – 2 (8.7) 2 (10.5) 4 (9.8%)
Vitreous floaters – 1 (4.3) 1 (5.3) 2 (4.8%)
Weight loss – 1 (4.3) – 1 (2.4%)
Decreased appetite – – 2 (10.5) 2 (4.8%)
Pulmonary embolism – 1 (4.3) 1 (5.3) 2 (4.8%)
Dyspnea – 1 (4.3) – 1 (2.4%)
Angina unstable – – 1 (5.3) 1 (2.4%)
Ataxia – – 1 (5.3) 1 (2.4%)
Lipase increased 2 (8.7) – 2 (4.8%)
Abdominal pain 1 (4.3) 1 (2.4%)
Blood lactic acid increased 1 (4.3) 1 (2.4%)
Hypophosphatemia 1 (2.9) 1 (2.4%)
Squamous cell carcinoma 1 (2.9) 1 (4.3) 2 (4.8%)
Basal cell carcinoma 1 (2.9) 1 (2.4%)
Cutaneous lupus erythematosus 1 (5.3) 1 (2.4%)
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Table 4. Antitumor response rates based on dose levels (DL) and BRAF mutation status.
DLs 1 to 4 
N = 20 
n (%)
DL 5 
N = 15 
n (%)
DL 6 
N = 23 
n (%)
DLs 7 and 7.1 
N = 19 
n (%)
All patients 
N = 77 
n (%)
Best overall response
BRAF mutation
Evaluable disease 6 8 10 9 33
Complete response (CR) 0 0 0 0 0
Partial response (PR) 2 (33.3) 1 (12.5) 1 (10) 0 4 (12)
Stable disease (SD) 0 3 (37.5) 7 (70) 5 (56) 15 (46)
Progressive disease (PD) 4 (66.7) 4 (50) 2 (20) 4 (44) 14 (42)
BRAF wild- type
Evaluable disease 8 5 8 7 28
Complete response (CR) 0 0 0 1 (14.3) 1 (3.6)
Partial response (PR) 1 (12.5) 0 1 (12.5) 0 2 (8)
Stable disease (SD) 1 (12.5) 3 (60) 2 (25) 5 (71.4) 11 (39.3)
Progressive disease (PD) 6 (75) 2 (40) 5 (62.5) 1 (14.3) 14 (50)
BRAF unspecified/unknown
Evaluable disease 1 0 2 2 5
Complete response (CR) 0 0 0 0 0
Partial response (PR) 0 0 0 1 (50) 1 (20)
Stable disease (SD) 1 (100) 0 0 0 1 (20)
Progressive disease (PD) 0 0 2 (100) 1 (50) 3 (60)
Total
Evaluable disease 15 13 20 18 66
Complete response (CR) 0 0 0 1 (5.6) 1 (1.5)
Partial response (PR) 3 (20) 1 (7.7) 2 (10) 1 (5.6) 7 (10.6)
Stable disease (SD) 2 (13.3) 6 (46.1) 9 (45) 10 (55.6) 27 (40.9)
Progressive disease (PD) 10 (66.7) 6 (46.1) 9 (45) 6 (33.3) 31 (47)
Best response
CR or PR 3 (20) 1 (7.7) 2 (10) 2 (11.1) 8 (12.1)
CR, PR or SD 5 (33.3) 7 (53.8) 11 (55) 12 (66.7) 35 (53)
SD or better after 12 months 3 (20) 1 (7.7) 2 (10) 1 (5.6) 7 (10.6)
Figure 1. Metabolic responses based on FDG- PET assessment. PMR partial metabolic response, SMD stable metabolic disease, PMD progressive 
metabolic disease. *indicates patients with PMD as defined in Methods.
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metabolic disease (PMD) on C1D28. Across all dose levels, 
10 of 65 (15.4%) patients had PMR, 46 (70.8%) had 
SMD and 9 (13.8%) had PMD on C1D15. PMR occurred 
in 8 of 28 (28.6%) patients with BRAF- mutant tumors, 
and 3 of 28 (10.7%) patients with BRAF- WT disease on 
C1D28. On C1D15 imaging, we observed PMR in 8 of 
33 (24.2%) patients with BRAF mutant tumors, and 1 
of 29 (3.4%) patients with BRAF WT disease. Responses 
occurred statistically more significant in patients with 
BRAF- mutant disease on C1D15 (P = 0.028; two- tailed 
Fisher’s test) and there was a trend toward higher meta-
bolic responses in these patients on C1D28 (P = 0.1808; 
two- tailed Fisher’s test). Five of eight patients with RECIST- 
defined responses also had partial metabolic response 
(Fig. 2).
In 23 patients, on- treatment biopsies were available for 
IHC analysis to assess for changes in biomarker expres-
sion compared to pretreatment biopsies (Tables S4 and 
S5). Across all dose levels, there was variability in expres-
sion changes, including significant increases and decreases 
in marker expression for the examined proteins and 
phospho- proteins. Cytoplasmic and nuclear p- ERK was 
modestly decreased in the on- treatment specimens of 
patients in DL6- 7.1, with median decrease in 13.4–50% 
and 7.6–22.2%, respectively. The median cytoplasmic 
p- ERK abundance was increased by 27–52.5% in patients 
treated with DL1- 5. Abundance of p- MEK and BIM were 
modestly changed. Interestingly, a dose- dependent increase 
in p27 abundance (median increase 30.4% and 72.2% 
in DL 6 and DL 7/7.1, respectively), and decrease in cyclin 
D1 (median decrease 25%) and Ki67 (up to 51.8% 
in DL 6) were seen, together indicating a decreased rate 
of entry into S- phase and proliferation. Although overall 
levels of p- AKT and pS6 showed only modest changes, 
both were decreased in DL 6 (median decrease 46.7% 
and 35.8%, respectively).
Statistically significant, dose- dependent changes in the 
modulation of the VEGF pathway across all dose levels 
over time were seen (Fig. 3). After 60 days of treatment, 
soluble VEGFR- 2 levels decreased by 15–42% from base-
line. In contrast, protein levels of placental growth factor 
increased by 50–150% in patients treated at dose levels 
6, 7 and 7.1.
Discussion
Here, we report the first in- human experience of the orally 
available, RAF/VEGFR- 2 inhibitor RAF265 in patients with 
locally advanced or metastatic melanoma. Overall, RAF265 
is an agent with a long serum half- life of ~8 days, and 
a MTD of 48 mg daily. Doses above 48 mg daily were 
associated with unacceptable acute, delayed and prolonged 
toxicity. Across the evaluable study population, the anti-
tumor response rate was 12.1%. Notably, these responses 
occurred in patients with tumors with or without BRAF 
mutation and across dose levels. Furthermore, metabolic 
responses were seen in 20.7% of patients, and significant 
alterations of placental growth factor and sVEGFR- 2, both 
key modulators of angiogenesis, were also observed.
The discovery of sensitizing BRAF mutations in mela-
noma provided a strong biologic rationale for the devel-
opment and the rapid implementation of BRAF- inhibitors 
into clinical trials. Preclinical studies showed that RAF265 
selectively inhibited BRAFV600E, CRAF, VEGFR- 2 and other 
targets at nanomolar EC50 concentrations [11–13]. This 
data suggested that RAF265 might produce superior results 
to those seen with sorafenib in patients with BRAF- mutant 
melanoma. While RAF265 showed a relatively low response 
rate and some significant and prolonged toxicities (par-
ticularly thrombocytopenia and visual problems) making 
its therapeutic index suboptimal for further pursuit, 
attempting to selectively target mutant BRAF proved to 
Figure 2. Relationship between RECIST- defined responders and metabolic responses. *indicates a patient with RECIST- defined CR.
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be a sound strategy as evident by the activity observed 
with more selective BRAF inhibitors such as vemurafenib 
and dabrafenib in this patient population. Specifically 
vemurafenib or dabrafenib either as single agents or in 
combination with the MEK- inhibitors cobimetinib or 
trametinib, produced objective response rates between 50% 
and 70%, and improved median progression- free and 
overall survival in patients with BRAF- mutant advanced 
or metastatic melanoma, leading to their FDA- approvals 
[18–22].
Preclinical data indicated that RAF265 had a similar 
an EC50 (=14 nmol/L for BRAFV600E) as vemurafenib. 
However, in comparison to vemurafenib, response rates 
were lower in BRAFV600E patients. A distinguishing feature 
of RAF265 from vemurafenib and dabrafenib is the clini-
cal activity in BRAF- WT patients. In contrast, RAF265 
seems to achieve plasma levels that are commensurate 
with active exposures in preclinical models; however, the 
agent may not have sufficient selectivity for BRAFV600E 
in most patients, as indicated by the increased incidence 
of thrombocytopenia and visual side effects—both more 
consistent with inhibition of wild- type BRAF and CRAF, 
and decreased incidence of skin squamous cell carcinoma. 
In line with this, we observed an increase in p- ERK 
expression in patients treated at DL1- 5, and moderately 
decreased p- ERK abundance in patients treated at DL 
6- 7.1. In comparison, vemurafenib suppresses pERK by 
well over 80% at the recommended phase II dose [23]. 
Overall, this highlights the need for highly selective inhibi-
tors in order to reduce off- target effects that result in 
toxicities, which collaterally limit tolerability of potentially 
clinical beneficial drugs, as seen with, for example, sorafenib 
in the treatment of either melanoma or renal cell cancer 
relative to either more selective BRAFV600 inhibitors (e.g. 
vemurafenib) for melanoma [24] or VEGF inhibitors (e.g., 
axitinib) in renal cell cancer [25].
We observed responses in patients with BRAF- WT 
melanoma, including a complete response. This is consist-
ent with preclinical observations of responses in BRAF- WT 
patient- derived xenografts treated with RAF265 [12] and 
other pan- RAF- inhibitors [14]. Given RAF265′s relatively 
high EC50 (>5 μmol/L) for the wild- type BRAF protein, 
it is conceivable that these responses were not due to 
BRAF inhibition. Inhibition of wild- type BRAF with vemu-
rafenib, dabrafenib and related BRAF inhibitors results 
in transactivation of alternative RAF- dimers and down-
stream activation of ERK [26]. However, RAF265 appears 
to inhibit MAPK pathway signaling in some RAS- mutant 
models [12]. It is plausible that responses in BRAF- WT 
patients stem from inhibition of other targets highlighting 
the pan- RAF inhibitor/multi- kinase inhibitor function of 
RAF265. These effects may be explained by inhibition of 
the MAPK pathway given that MEK inhibitors are associ-
ated with responses in BRAF WT melanoma [27, 28], 
and other cell autonomous or cell non- autonomous mecha-
nisms, which is supported by our biomarker analysis. First, 
our biomarker analysis indicates that RAF265 also interferes 
with the AKT pathway, S- phase entry and cell prolifera-
tion, supporting properties of a multi- kinase inhibitor. 
In support of the latter, we observed a significant decrease 
Figure 3. Relative protein abundance of placental growth factor (PGIF) and soluble VEGFR- 2 (sVEGFR- 2) measured in blood across dose levels.
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in sVEGFR- 2 levels over time across all dose levels. At 
the same time, we observed increased levels of placental 
growth factor, one of the VEGFR- 1 ligands, emphasizing 
the modulatory effects of RAF265 on angiogenesis. 
Clinically this is also reflected the development of hyper-
tension in 17% of patients (Table 2), a common side 
effect of anti- VEGF directed therapy. Previous studies, 
including a phase II trial with the VEGFR1- 3 inhibitor 
axitinib, demonstrated a ~19% response rate in patients 
with metastatic melanoma [15]. Furthermore, the role of 
anti- angiogenic therapies in combination with other treat-
ments, such as immune checkpoint inhibitors or chemo-
therapy, is currently under study as a treatment option 
for patients with metastatic melanoma [29].
Responses to RAF265 in BRAF- WT patients may also 
be associated with alternative mutations that were not 
systematically evaluated in this study, such as mutations 
in NRAS, which occur mutually exclusive from BRAF 
mutations in ~25% of patients, non- V600E BRAF muta-
tions in ~5–10% of patients, NF1 in ~10–15% of patients 
and PTEN loss, which is found in ~10% of melanoma 
and occur with or without concomitant BRAF mutation 
[6, 7].
We observed partial metabolic responses in 20.7% and 
stable metabolic disease in 43% of patients. Previous work 
found a correlation between metabolic and RECIST- defined 
responses in patients with BRAF- mutant melanoma treated 
with vemurafenib [30]. While our analysis is limited by 
a small number of patients with both clinical and con-
comitant metabolic responses, we find that five of eight 
RAF265- treated patients with RECIST- defined response 
(PR or CR) also had partial metabolic responses (Fig. 2). 
Changes in glucose metabolism in BRAF- mutant melanoma 
have been suggested as physiologic basis of BRAF- inhibitor 
associated PET- CT responses, and may underlie changes 
identified in this study [30–32]. However, discordant 
metabolic and RECIST- response in two patients in our 
study indicate that other metabolic pathways may be 
related to RAF/VEGFR- 2 induced antitumor activity.
Treatment options for patients with BRAF WT patients 
primarily include immune checkpoint inhibitors and HD- 
IL2. Immune checkpoint inhibitors, such as ipilimumab, 
nivolumab and pembrolizumab either as single agents, or 
nivolumab and ipilimumab in combination, produce durable 
responses in 10 to over 50% of patients [33–38]. Choosing 
the most effective treatment for patients with BRAF- WT 
melanoma who have not responded or are ineligible for 
immunotherapy remains a clinical challenge. In this context, 
our study highlights the necessity to obtain a deeper under-
standing of genetic predictors for response—beyond BRAF—
in order to identify subsets, where therapies such as RAF265 
or other pan- RAF inhibitors might be beneficial.
In conclusion, we have shown that RAF265, an orally 
available RAF/VEGFR- 2 inhibitor, produces clinical and 
metabolic responses in a subset of patients with locally 
advanced or metastatic melanoma, including patients with 
BRAF- WT disease. The MTD was determined to be 48 mg 
PO daily as higher doses produced visual problems and 
prolong thrombocytopenia. Furthermore, RAF265 signifi-
cantly modulates key regulators of angiogenesis, including 
VEGFR- 2 and PGIF. A long half- life and prolonged tox-
icities along with a relatively low response rate indicate 
that RAF265 has limited selectivity or activity for BRAF 
in vivo. This marginal therapeutic index together with 
the advent of other much more effective and selective 
BRAFV600 inhibitors resulted in the phase II dose expan-
sion study being cancelled. Responses in patients with 
BRAF- WT melanoma indicate that the development of 
more specific pan- RAF inhibitors may provide a feasible 
therapeutic avenue for these patients. This study also 
provides rationale to continue ongoing efforts investigating 
the combination of VEGFR- 2 targeted therapies with 
immunotherapies.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Table S1. Definition of dose limiting toxicities (DLTs).
Table S2. Scheme of eight dose levels. At each dose level, 
with the exception of DL 8, patients received a 7–10 days 
run- in dose, followed by a single loading dose (LD) and a 
daily maintenance dose (MD). *administered as three doses.
Table S3. Pharmacokinetics of RAF265.
Table S4. Changes in expression of cytosolic biomarkers. 
Patients included in this analysis had a fresh or archival 
tissue scored as described in the methods section. Changes 
of biomarker abundance were evaluated in on- treatment 
specimens. Shown is the number of patients with tissue 
available for each biomarker analysis, mean and median 
% changes compared to the pretreatment specimen, and 
the range for each biomarker in each dose level and in 
the entire evaluable population. **pMEK, phosphorylated 
MAPK/ERK kinase; pERK, phosphorylated extracellar 
signal- regulated kinase; Ki67, proliferation- associated anti-
gen Ki- 67; BIM, a pro- apoptotic member of the BCL- 2 
family; PARP, poly(ADP- ribose)polymerase; Cyclin D1, 
cell cycle gene, MITF, microphthalmia- associated tran-
scription factor; CKIT, c- KIT; P53, tumor protein 53/
TP53; PAKT473, phospho Akt S 473; PS6, phosphoserine 
240- S6 ribosomal protein; PTEN, phosphatase and tensin 
homolog.
Table S5. Changes in expression of nuclear biomarkers.
